Abstract
Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (
| Original language | English |
|---|---|
| Pages (from-to) | 1921-1927 |
| Number of pages | 7 |
| Journal | Annals of Oncology |
| Volume | 16 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2005 |
Fingerprint
Keywords
- Anemia
- Darbepoetin alfa
- Erythropoietin
- Myelodysplastic syndrome
- Predictive factors
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. / Stasi, Roberto; Abruzzese, E.; Lanzetta, G.; Terzoli, E.; Amadori, S.
In: Annals of Oncology, Vol. 16, No. 12, 12.2005, p. 1921-1927.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
AU - Stasi, Roberto
AU - Abruzzese, E.
AU - Lanzetta, G.
AU - Terzoli, E.
AU - Amadori, S.
PY - 2005/12
Y1 - 2005/12
N2 - Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (
AB - Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS). Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 μg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response. Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 μg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P <0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (
KW - Anemia
KW - Darbepoetin alfa
KW - Erythropoietin
KW - Myelodysplastic syndrome
KW - Predictive factors
UR - http://www.scopus.com/inward/record.url?scp=28444489284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28444489284&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdi400
DO - 10.1093/annonc/mdi400
M3 - Article
VL - 16
SP - 1921
EP - 1927
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 12
ER -